What is the difference between CagriSema and Liraglutide?

CagriSema: CagriSema is Novo Nordisk's investigational fixed combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). By pairing two complementary appetite pathways, it produced roughly 20–23% weight loss in trials. It was filed with the FDA in December 2025 but is not yet approved — and notably missed non-inferiority against tirzepatide in a head-to-head study. Liraglutide: Liraglutide is a once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analog approved for both type 2 diabetes (Victoza, 1.8mg) and chronic weight management (Saxenda, 3mg). It was the foundational GLP-1 agonist that established the class's cardiovascular benefits and set the stage for semaglutide and tirzepatide. Both are in the GLP-1 & Metabolic category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take CagriSema and Liraglutide together?

There is no specific, well-documented interaction rule for combining CagriSema and Liraglutide in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, CagriSema or Liraglutide?

CagriSema is currently investigational (in trials) and Liraglutide is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

GLP-1 & Metabolic · Comparison

CagriSema vs Liraglutide

A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CagriSema

Investigational (in trials)

CagriSema is Novo Nordisk's investigational fixed combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). By pairing two complementary appetite pathways, it produced roughly 20–23% weight loss in trials. It was filed with the FDA in December 2025 but is not yet approved — and notably missed non-inferiority against tirzepatide in a head-to-head study.

Full profile

Liraglutide

FDA-approved

Liraglutide is a once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analog approved for both type 2 diabetes (Victoza, 1.8mg) and chronic weight management (Saxenda, 3mg). It was the foundational GLP-1 agonist that established the class's cardiovascular benefits and set the stage for semaglutide and tirzepatide.

Full profile

	CagriSema	Liraglutide
Category	GLP-1 & Metabolic	GLP-1 & Metabolic
Also known as	Cagrilintide + Semaglutide, AM833 + semaglutide, amylin/GLP-1 combination	NN2211, Victoza, Saxenda
Evidence	Investigational (in trials)	FDA-approved
Dosing range	0.25mg–2.4mg mg, once weekly subcutaneous (each component 2.4mg at target)	0.6mg–3.0mg mg, Once daily subcutaneous injection
Administration	Subcutaneous injection (weekly)	Subcutaneous injection (abdomen, thigh, or upper arm)
Key side effects	Nausea (most common, dose-dependent), Vomiting, Diarrhea or constipation, Decreased appetite	Nausea (most common, especially during initiation), Vomiting, Diarrhea, Decreased appetite
Cited sources	2 references	2 references

Key differences

Evidence level differs: CagriSema is investigational (in trials), while Liraglutide is fda-approved.
Administration: CagriSema — Subcutaneous injection (weekly); Liraglutide — Subcutaneous injection (abdomen, thigh, or upper arm).
Frequency: CagriSema is typically once weekly subcutaneous (each component 2.4mg at target); Liraglutide is Once daily subcutaneous injection.

How each works

CagriSema

CagriSema combines amylin-receptor agonism (cagrilintide — satiety and gastric emptying via the area postrema/hypothalamus) with GLP-1 agonism (semaglutide), two non-overlapping appetite mechanisms. The REDEFINE 1 and 2 trials supported a December 2025 FDA filing for weight management. However, the open-label REDEFINE-4 head-to-head trial showed 23.0% weight loss vs 25.5% for tirzepatide 15 mg, missing its primary non-inferiority endpoint. An FDA decision is expected in late 2026.

Liraglutide

The LEADER trial (N=9340) demonstrated significant reduction in major adverse cardiovascular events (MACE) in high-risk T2D patients — the first cardiovascular outcomes trial for a GLP-1 agonist. The SCALE trials showed 5–8% mean weight loss at 3mg/day vs placebo. While superseded by semaglutide and tirzepatide in weight loss efficacy, liraglutide has the longest safety record in the class (approved 2010) and daily dosing allows finer tolerability titration.

Read the full CagriSema profile Read the full Liraglutide profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.